LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: TAp73 represses NF-κB-mediated recruitment of tumor-associated macrophages in breast cancer.

    Wolfsberger, Johanna / Sakil, Habib A M / Zhou, Leilei / van Bree, Niek / Baldisseri, Elena / de Souza Ferreira, Sabrina / Zubillaga, Veronica / Stantic, Marina / Fritz, Nicolas / Hartman, Johan / Rolny, Charlotte / Wilhelm, Margareta T

    Proceedings of the National Academy of Sciences of the United States of America

    2021  Volume 118, Issue 10

    Abstract: Infiltration of tumor-promoting immune cells is a strong driver of tumor progression. Especially the accumulation of macrophages in the tumor microenvironment is known to facilitate tumor growth and to correlate with poor prognosis in many tumor types. ... ...

    Abstract Infiltration of tumor-promoting immune cells is a strong driver of tumor progression. Especially the accumulation of macrophages in the tumor microenvironment is known to facilitate tumor growth and to correlate with poor prognosis in many tumor types. TAp73, a member of the p53/p63/p73 family, acts as a tumor suppressor and has been shown to suppress tumor angiogenesis. However, what role TAp73 has in regulating immune cell infiltration is unknown. Here, we report that low levels of TAp73 correlate with an increased NF-κB-regulated inflammatory signature in breast cancer. Furthermore, we show that loss of TAp73 results in NF-κB hyperactivation and secretion of Ccl2, a known NF-κB target and chemoattractant for monocytes and macrophages. Importantly, TAp73-deficient tumors display an increased accumulation of protumoral macrophages that express the mannose receptor (CD206) and scavenger receptor A (CD204) compared to controls. The relevance of TAp73 expression in human breast carcinoma was further accentuated by revealing that TAp73 expression correlates negatively with the accumulation of protumoral CD163
    MeSH term(s) Animals ; Antigens, CD/immunology ; Antigens, Differentiation, Myelomonocytic/immunology ; Breast Neoplasms/immunology ; Breast Neoplasms/pathology ; Chemokine CCL2/immunology ; Female ; Humans ; Membrane Glycoproteins/immunology ; Mice ; NF-kappa B/immunology ; Receptors, Cell Surface/immunology ; Receptors, Immunologic/immunology ; Scavenger Receptors, Class A/immunology ; Signal Transduction/immunology ; Tumor Microenvironment/immunology ; Tumor Protein p73/immunology ; Tumor-Associated Macrophages/immunology ; Tumor-Associated Macrophages/pathology
    Chemical Substances Antigens, CD ; Antigens, Differentiation, Myelomonocytic ; CCL2 protein, human ; CD163 antigen ; Chemokine CCL2 ; MRC1 protein, human ; MSR1 protein, human ; Membrane Glycoproteins ; NF-kappa B ; Receptors, Cell Surface ; Receptors, Immunologic ; Scavenger Receptors, Class A ; Tumor Protein p73
    Language English
    Publishing date 2021-02-26
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 209104-5
    ISSN 1091-6490 ; 0027-8424
    ISSN (online) 1091-6490
    ISSN 0027-8424
    DOI 10.1073/pnas.2017089118
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation.

    Bezzerri, Valentino / Gentili, Valentina / Api, Martina / Finotti, Alessia / Papi, Chiara / Tamanini, Anna / Boni, Christian / Baldisseri, Elena / Olioso, Debora / Duca, Martina / Tedesco, Erika / Leo, Sara / Borgatti, Monica / Volpi, Sonia / Pinton, Paolo / Cabrini, Giulio / Gambari, Roberto / Blasi, Francesco / Lippi, Giuseppe /
    Rimessi, Alessandro / Rizzo, Roberta / Cipolli, Marco

    Nature communications

    2023  Volume 14, Issue 1, Page(s) 132

    Abstract: As an inherited disorder characterized by severe pulmonary disease, cystic fibrosis could be considered a comorbidity for coronavirus disease 2019. Instead, current clinical evidence seems to be heading in the opposite direction. To clarify whether host ... ...

    Abstract As an inherited disorder characterized by severe pulmonary disease, cystic fibrosis could be considered a comorbidity for coronavirus disease 2019. Instead, current clinical evidence seems to be heading in the opposite direction. To clarify whether host factors expressed by the Cystic Fibrosis epithelia may influence coronavirus disease 2019 progression, here we describe the expression of SARS-CoV-2 receptors in primary airway epithelial cells. We show that angiotensin converting enzyme 2 (ACE2) expression and localization are regulated by Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel. Consistently, our results indicate that dysfunctional CFTR channels alter susceptibility to SARS-CoV-2 infection, resulting in reduced viral entry and replication in Cystic Fibrosis cells. Depending on the pattern of ACE2 expression, the SARS-CoV-2 spike (S) protein induced high levels of Interleukin 6 in healthy donor-derived primary airway epithelial cells, but a very weak response in primary Cystic Fibrosis cells. Collectively, these data support that Cystic Fibrosis condition may be at least partially protecting from SARS-CoV-2 infection.
    MeSH term(s) Humans ; Angiotensin-Converting Enzyme 2/genetics ; Angiotensin-Converting Enzyme 2/metabolism ; COVID-19 ; Cystic Fibrosis/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/metabolism ; Down-Regulation ; Receptors, Virus/genetics ; Receptors, Virus/metabolism ; SARS-CoV-2/physiology ; Spike Glycoprotein, Coronavirus/metabolism ; Virus Internalization ; Virus Replication
    Chemical Substances Angiotensin-Converting Enzyme 2 (EC 3.4.17.23) ; Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6) ; Receptors, Virus ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; ACE2 protein, human (EC 3.4.17.23)
    Language English
    Publishing date 2023-01-10
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-023-35862-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells.

    Cipolli, Marco / Boni, Christian / Penzo, Marianna / Villa, Isabella / Bolamperti, Simona / Baldisseri, Elena / Frattini, Annalisa / Porta, Giovanni / Api, Martina / Selicato, Nora / Roccia, Pamela / Pollutri, Daniela / Marinelli Busilacchi, Elena / Poloni, Antonella / Caporelli, Nicole / D'Amico, Giovanna / Pegoraro, Anna / Cesaro, Simone / Oyarbide, Usua /
    Vella, Antonio / Lippi, Giuseppe / Corey, Seth J / Valli, Roberto / Polini, Alessandro / Bezzerri, Valentino

    British journal of haematology

    2023  Volume 204, Issue 1, Page(s) 292–305

    Abstract: Shwachman-Diamond syndrome (SDS) is characterized by neutropenia, exocrine pancreatic insufficiency and skeletal abnormalities. SDS bone marrow haematopoietic progenitors show increased apoptosis and impairment in granulocytic differentiation. Loss of ... ...

    Abstract Shwachman-Diamond syndrome (SDS) is characterized by neutropenia, exocrine pancreatic insufficiency and skeletal abnormalities. SDS bone marrow haematopoietic progenitors show increased apoptosis and impairment in granulocytic differentiation. Loss of Shwachman-Bodian-Diamond syndrome (SBDS) expression results in reduced eukaryotic 80S ribosome maturation. Biallelic mutations in the SBDS gene are found in ~90% of SDS patients, ~55% of whom carry the c.183-184TA>CT nonsense mutation. Several translational readthrough-inducing drugs aimed at suppressing nonsense mutations have been developed. One of these, ataluren, has received approval in Europe for the treatment of Duchenne muscular dystrophy. We previously showed that ataluren can restore full-length SBDS protein synthesis in SDS-derived bone marrow cells. Here, we extend our preclinical study to assess the functional restoration of SBDS capabilities in vitro and ex vivo. Ataluren improved 80S ribosome assembly and total protein synthesis in SDS-derived cells, restored myelopoiesis in myeloid progenitors, improved neutrophil chemotaxis in vitro and reduced neutrophil dysplastic markers ex vivo. Ataluren also restored full-length SBDS synthesis in primary osteoblasts, suggesting that its beneficial role may go beyond the myeloid compartment. Altogether, our results strengthened the rationale for a Phase I/II clinical trial of ataluren in SDS patients who harbour the nonsense mutation.
    MeSH term(s) Humans ; Shwachman-Diamond Syndrome ; Tumor Suppressor Protein p53/genetics ; Lipomatosis/genetics ; Codon, Nonsense ; Myelopoiesis ; Neutrophils/metabolism ; Chemotaxis ; Bone Marrow Diseases/genetics ; Bone Marrow Diseases/therapy ; Exocrine Pancreatic Insufficiency/genetics ; Ribosomes/metabolism
    Chemical Substances ataluren (K16AME9I3V) ; Tumor Suppressor Protein p53 ; Codon, Nonsense
    Language English
    Publishing date 2023-10-24
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.19134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: In silico

    Kleinfelder, Karina / Lotti, Virginia / Eramo, Adriana / Amato, Felice / Lo Cicero, Stefania / Castelli, Germana / Spadaro, Francesca / Farinazzo, Alessia / Dell'Orco, Daniele / Preato, Sara / Conti, Jessica / Rodella, Luca / Tomba, Francesco / Cerofolini, Angelo / Baldisseri, Elena / Bertini, Marina / Volpi, Sonia / Villella, Valeria Rachela / Esposito, Speranza /
    Zollo, Immacolata / Castaldo, Giuseppe / Laudanna, Carlo / Sorsher, Eric J / Hong, Jeong / Joshi, Disha / Cutting, Garry / Lucarelli, Marco / Melotti, Paola / Sorio, Claudio

    iScience

    2023  Volume 26, Issue 11, Page(s) 108180

    Abstract: Mutation targeted therapy in cystic fibrosis (CF) is still not eligible for all CF subjects, especially for cases carrying rare variants such as the CFTR genotype W57G/A234D (c.169T>G/c.701C>A). We ... ...

    Abstract Mutation targeted therapy in cystic fibrosis (CF) is still not eligible for all CF subjects, especially for cases carrying rare variants such as the CFTR genotype W57G/A234D (c.169T>G/c.701C>A). We performed
    Language English
    Publishing date 2023-10-12
    Publishing country United States
    Document type Journal Article
    ISSN 2589-0042
    ISSN (online) 2589-0042
    DOI 10.1016/j.isci.2023.108180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top